BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21690267)

  • 1. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
    Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.
    Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H
    Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
    Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
    Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
    Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism.
    Vandenbosch K; Renard M; Uyttebroeck A; Sciot R; Matthijs G; Legius E
    Genet Couns; 2005; 16(1):95-100. PubMed ID: 15844786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
    Sawai H; Okada Y; Kazanjian K; Kim J; Hasan S; Hines OJ; Reber HA; Hoon DS; Eibl G
    Cancer Res; 2005 Dec; 65(24):11536-44. PubMed ID: 16357163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
    Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.
    Muzza M; Cordella D; Bombled J; Bressac-de Paillerets B; Guizzardi F; Francis Z; Beck-Peccoz P; Schlumberger M; Persani L; Fugazzola L
    Eur J Endocrinol; 2010 Apr; 162(4):771-7. PubMed ID: 20103606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
    Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
    Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neural crest and multiple endocrinopathies].
    Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
    C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.